MAP2K7 and cancer: Thus, combination with other therapies—especially immune-based therapies such as ICI—has been sought after to potentially synergize with the cancer cell death (and subsequent antigen presentation and T-cell infiltration) induced by RAF and MEK inhibitors [78,79].